Recursion Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	743.29	594.35	391.57	549.91	285.12
Short-Term Investments	-	-	-	-	231.45
Cash & Short-Term Investments	743.29	594.35	391.57	549.91	516.56
Cash Growth	25.06%	51.79%	-28.79%	6.46%	97.07%
Accounts Receivable	-	-	-	-	0.03
Other Receivables	24.65	49.17	3.09	2.75	9.06
Total Trade Receivables	24.65	49.17	3.09	2.75	9.09
Other Current Assets	44.9	70.75	43.48	17.15	9.07
Total Current Assets	812.85	714.27	438.14	569.81	534.72
Net Property, Plant & Equipment	169.48	233.21	120.17	121.45	64.73
Other Intangible Assets	309.9	335.86	36.44	1.31	1.39
Goodwill	162.16	148.87	52.06	0.8	0.8
Other Long-Term Assets	19.74	16.39	6.89	7.92	8.72
Total Assets	1,474	1,449	653.7	701.29	610.35
Accounts Payable	18.12	21.61	3.95	4.59	2.82
Accrued Expenses	70.23	81.87	46.64	32.9	32.33
Short-Term Debt	9.09	8.43	0.04	0.1	0.09
Current Portion of Leases	12.66	13.8	6.12	5.95	-
Unearned Revenue	37.61	61.77	36.43	56.73	10
Other Current Liabilities	-	-	-	-	1.42
Total Current Liabilities	147.71	187.47	93.17	100.27	46.66
Long-Term Debt	9.56	19.02	1.1	0.54	0.63
Long-Term Leases	46.65	67.25	43.41	44.42	-
Other Long-Term Liabilities	139.35	140.07	52.58	70.26	20.12
Total Long-Term Liabilities	195.56	226.34	97.09	115.22	20.75
Total Liabilities	343.27	413.82	190.26	215.48	67.41
Common Stock	0.01	0	0	0	0
Additional Paid-in Capital	3,170	2,474	1,431	1,125	943.14
Accumulated Other Comprehensive Income	36.72	-7.64	-	-	-0.13
Retained Earnings	-2,076	-1,431	-967.62	-639.56	-400.08
Total Common Shareholders' Equity	1,131	1,035	463.44	485.81	542.94
Shareholders' Equity	1,131	1,035	463.44	485.81	542.94
Total Liabilities & Equity	1,474	1,449	653.7	701.29	610.35
Total Debt	77.97	108.49	50.67	51.01	0.72
Net Cash (Debt)	665.33	485.86	340.89	498.91	515.84
Net Cash Growth	36.94%	42.52%	-31.67%	-3.28%	106.63%
Net Cash Per Share	1.49	1.77	1.64	2.84	4.12
Book Value	1,131	1,035	463.44	485.81	542.94
Book Value Per Share	2.53	3.77	2.23	2.77	4.33
Tangible Book Value	658.8	550.05	374.94	483.7	540.75
Tangible Book Value Per Share	1.47	2.01	1.80	2.76	4.31

Updated Feb 25, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q